Results 181 to 190 of about 5,782,005 (384)
HETEROGENEITY OF MYELOMA PROTEINS [PDF]
Journal of Clinical Investigation, 1963 openaire +3 more sources
The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells _in vitro_ and _in vivo_ [PDF]
, 2008 CD138 (Syndecan1) is highly expressed on multiple myeloma (MM) cells. In this study, we examined the anti-MM effect of murine/human chimeric CD138-specific monoclonal antibody (mAb) nBT062 conjugated with highly cytotoxic maytansinoid derivatives _in ...
Benjamin Dä +20 more
core +1 more source
Cancer Communications, EarlyView.Abstract Post‐translational modifications (PTMs) play a pivotal role in epigenetic regulation and are key pathways for modulating protein functionality. PTMs involve the covalent attachment of distinct chemical groups, such as succinyl, crotonyl, and lactyl, at specific protein sites, which alter protein structure, function, stability, and activity ...
Ting Wu +16 more
wiley +1 more source
Bee‐Derived Antioxidants as a Protective Strategy Against Doxorubicin‐Induced Ovarian Damage
Chemistry &Biodiversity, EarlyView.Graphical abstract of Bee‐Derived Antioxidants as a Protective Strategy Against Doxorubicin‐Induced Ovarian Damage ABSTRACT Antineoplastic agents can induce tissue damage through oxidative stress mechanisms. Doxorubicin, a widely used chemotherapeutic agent, has been shown to cause permanent damage to reproductive tissues.
Meltem Arıkan Malkoc +3 more
wiley +1 more source
Chromenone Derivatives as CRM1 Inhibitors for Targeting Glioblastoma
ChemBioChem, EarlyView.Chromenone derivatives are synthesized and evaluated as inhibitors of chromosome region maintenance 1‐mediated nuclear export, targeting glioblastoma cells. Active compounds demonstrate structure‐ and dose‐dependent inhibition, supported by structure–activity relationships and molecular docking studies.
Salvatore Princiotto +10 more
wiley +1 more source
Model‐Informed Drug Development Applications and Opportunities in mRNA‐LNP Therapeutics
Clinical Pharmacology &Therapeutics, EarlyView.The utilization of lipid nanoparticles (LNP) for encapsulating mRNA has revolutionized the field of therapeutics, enabling the rapid development of COVID‐19 vaccines and cancer vaccines. However, the clinical development of mRNA‐LNP therapeutics faces numerous challenges due to their complex mechanisms of action and limited clinical experience.
Jiawei Zhou +6 more
wiley +1 more source
Sequence variation among heavy chains from inulin-binding myeloma proteins [PDF]
, 1978 Mark Vrana +2 more
openalex +1 more source
Expert Perspective: Hematologic Malignancies and Vasculitis
Arthritis &Rheumatology, EarlyView.
Michelle L. Robinette, Hetty E. Carraway
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Talquetamab is the first and only GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). In the phase I/II MonumenTAL‐1 study, overall response rates (ORRs) were > 66% in patients with RRMM treated with subcutaneous talquetamab at the recommended phase II doses (RP2Ds): 0.4 mg/kg weekly and 0.8 mg/kg every other week.
Jue Gong +16 more
wiley +1 more source